Trial Outcomes & Findings for Wave Crossover ECP Study for Simplified Therapy (NCT NCT06571370)

NCT ID: NCT06571370

Last Updated: 2026-04-07

Results Overview

The primary effectiveness endpoint was the average Diastolic Augmentation (DA) ratio for the 8th minute of compressions with each ECP device tested for each participant, as identified by the blinded Independent Waveform Evaluator. Diastolic Augmentation (DA) ratio, also referred to as Diastolic/Systolic (D/S) ratio and Effectiveness Ratio (ER), noninvasively characterizes the hemodynamic effect and thus the clinical effectiveness of ECP treatment. DA ratio is a unitless measure which is "calculated as the ratio of the peak diastolic amplitude divided by the peak systolic amplitude" \[Suresh et al., 1998\]. In a typical, non-augmented, cardiac cycle, the diastolic peak is seen as a small increase in the arterial waveform just after the aortic valve closes (dicrotic notch). With augmentation, the peak diastolic amplitude is distinctly elevated and may reach a significant proportion of the peak systolic amplitude or in some cases exceed it.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

52 participants

Primary outcome timeframe

During treatment, measured at the 8th minute of compressions

Results posted on

2026-04-07

Participant Flow

60 subjects screened - 8 screen fails = 52 subjects randomized

Participant milestones

Participant milestones
Measure
Pression Wave PRO ECP System, Then Predicate ECP Device
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
Predicate ECP Device, Then Pression Wave PRO ECP System
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
First ECP Round (Day 0)
STARTED
26
26
First ECP Round (Day 0)
COMPLETED
25
26
First ECP Round (Day 0)
NOT COMPLETED
1
0
Second ECP Round (Day 0)
STARTED
25
26
Second ECP Round (Day 0)
COMPLETED
22
26
Second ECP Round (Day 0)
NOT COMPLETED
3
0
Evaluable Data Determination
STARTED
22
26
Evaluable Data Determination
COMPLETED
21
26
Evaluable Data Determination
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Pression Wave PRO ECP System, Then Predicate ECP Device
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
Predicate ECP Device, Then Pression Wave PRO ECP System
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
First ECP Round (Day 0)
PPG signal could not be obtained
1
0
Second ECP Round (Day 0)
Withdrawal by Subject
3
0
Evaluable Data Determination
Data file corrupted
1
0

Baseline Characteristics

Wave Crossover ECP Study for Simplified Therapy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pression Wave PRO ECP System, Then Predicate ECP Device
n=25 Participants
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
Predicate ECP Device, Then Pression Wave PRO ECP System
n=26 Participants
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
Total
n=51 Participants
Total of all reporting groups
Race (NIH/OMB)
Black or African American
11 Participants
n=527 Participants
13 Participants
n=527 Participants
24 Participants
n=1054 Participants
Age, Continuous
60.9 Years
STANDARD_DEVIATION 9.2 • n=527 Participants
60.8 Years
STANDARD_DEVIATION 9.1 • n=527 Participants
60.9 Years
STANDARD_DEVIATION 9.1 • n=1054 Participants
Sex: Female, Male
Female
17 Participants
n=527 Participants
7 Participants
n=527 Participants
24 Participants
n=1054 Participants
Sex: Female, Male
Male
8 Participants
n=527 Participants
19 Participants
n=527 Participants
27 Participants
n=1054 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=527 Participants
0 Participants
n=527 Participants
1 Participants
n=1054 Participants
Race (NIH/OMB)
Asian
1 Participants
n=527 Participants
0 Participants
n=527 Participants
1 Participants
n=1054 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=527 Participants
0 Participants
n=527 Participants
0 Participants
n=1054 Participants
Race (NIH/OMB)
White
11 Participants
n=527 Participants
12 Participants
n=527 Participants
23 Participants
n=1054 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=527 Participants
1 Participants
n=527 Participants
1 Participants
n=1054 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=527 Participants
0 Participants
n=527 Participants
1 Participants
n=1054 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=527 Participants
0 Participants
n=527 Participants
1 Participants
n=1054 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants
n=527 Participants
26 Participants
n=527 Participants
50 Participants
n=1054 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=527 Participants
0 Participants
n=527 Participants
0 Participants
n=1054 Participants
Body Mass Index (BMI
31.6 kg/m^2
STANDARD_DEVIATION 6.5 • n=527 Participants
33.7 kg/m^2
STANDARD_DEVIATION 7.1 • n=527 Participants
32.6 kg/m^2
STANDARD_DEVIATION 6.8 • n=1054 Participants
Fitzpatrick Skin Type
Type I (Pale white skin; red or blond hair; blue/green eyes; freckles)
3 Participants
n=527 Participants
0 Participants
n=527 Participants
3 Participants
n=1054 Participants
Fitzpatrick Skin Type
Type II (Fair skin; red or blond hair; blue, hazel, or green eyes)
6 Participants
n=527 Participants
4 Participants
n=527 Participants
10 Participants
n=1054 Participants
Fitzpatrick Skin Type
Type III (Darker white; any eye or hair color)
3 Participants
n=527 Participants
7 Participants
n=527 Participants
10 Participants
n=1054 Participants
Fitzpatrick Skin Type
Type IV (Light brown skin)
2 Participants
n=527 Participants
2 Participants
n=527 Participants
4 Participants
n=1054 Participants
Fitzpatrick Skin Type
Type V (Brown skin)
7 Participants
n=527 Participants
10 Participants
n=527 Participants
17 Participants
n=1054 Participants
Fitzpatrick Skin Type
Type VI (Dark brown or black skin)
4 Participants
n=527 Participants
3 Participants
n=527 Participants
7 Participants
n=1054 Participants

PRIMARY outcome

Timeframe: During treatment, measured at the 8th minute of compressions

Population: Modified ITT population of subjects who completed ECP compressions with both devices, Pression Wave PRO and Predicate (active comparator)

The primary effectiveness endpoint was the average Diastolic Augmentation (DA) ratio for the 8th minute of compressions with each ECP device tested for each participant, as identified by the blinded Independent Waveform Evaluator. Diastolic Augmentation (DA) ratio, also referred to as Diastolic/Systolic (D/S) ratio and Effectiveness Ratio (ER), noninvasively characterizes the hemodynamic effect and thus the clinical effectiveness of ECP treatment. DA ratio is a unitless measure which is "calculated as the ratio of the peak diastolic amplitude divided by the peak systolic amplitude" \[Suresh et al., 1998\]. In a typical, non-augmented, cardiac cycle, the diastolic peak is seen as a small increase in the arterial waveform just after the aortic valve closes (dicrotic notch). With augmentation, the peak diastolic amplitude is distinctly elevated and may reach a significant proportion of the peak systolic amplitude or in some cases exceed it.

Outcome measures

Outcome measures
Measure
Pression Wave PRO ECP System
n=95 Waveforms
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
Predicate ECP Device
n=48 Participants
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
Diastolic Augmentation
0.83 Ratio
Interval 0.77 to 0.88
0.57 Ratio
Interval 0.52 to 0.62

SECONDARY outcome

Timeframe: At last compression after 10 minutes of compression

Population: Analyzed only for Pression Wave PRO ECP results. Due to the way that the predicate device records waveform data, Sponsor was unable to evaluate systolic unloading for the predicate ECP device.

The level of systolic unloading was recorded based on the systolic peaks during compressions compared to baseline PPG data. Systolic unloading is the percent change of peak systolic amplitude calculated as the difference of the compression waveform - non-compressed baseline waveform divided by amplitude at compression waveform. Systolic unloading components were measured using the peak systolic amplitude on the last compression waveform from the ECP session. The baseline non-compressed peak systolic amplitude was measured from the waveform immediately following the compressed waveform. Higher levels of systolic unloading are considered better. The predicate devices are documented to produce mean systolic unloading of approximately 11%.

Outcome measures

Outcome measures
Measure
Pression Wave PRO ECP System
n=47 Participants
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
Predicate ECP Device
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
Systolic Unloading (Mean)
9.2 Percent change of peak systolic pressure
Standard Deviation 22.8

SECONDARY outcome

Timeframe: At last compression after 10 minutes of compression

Population: Due to the way that the predicate device records waveform data, Sponsor was unable to evaluate systolic unloading for the predicate ECP device.

Systolic unloading is the ratio of the systolic peak during compressions divided by baseline systolic peak. Systolic unloading is represented by a percentage decrease of systolic peak value with and without compression. This value should be \< 1. The baseline systolic peaks after compressions will be used. Higher levels of systolic unloading are considered better. The predicate devices are documented to produce mean systolic unloading of approximately 11%.

Outcome measures

Outcome measures
Measure
Pression Wave PRO ECP System
n=47 Participants
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
Predicate ECP Device
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
Systolic Unloading (Categorical)
<11%
27 Participants
Systolic Unloading (Categorical)
>=11%
20 Participants

Adverse Events

Pression Wave PRO ECP System, Then Predicate ECP Device

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Predicate ECP Device, Then Pression Wave PRO ECP System

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Adam Salamon, Study Director

Pression, Inc.

Phone: 215-326-9525

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place